EUVIMEDEUVIMED entdecken
Übersichtsarbeit

SOHO State of the Art Updates and Next Questions | Current Status and Future Directions of Donor Selection

Rohtesh S Mehta

Clinical Lymphoma Myeloma and Leukemia · 2024

DOI: 10.1016/j.clml.2024.05.011 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Rohtesh S Mehta. Beteiligte Einrichtung: Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA. Electronic address: rmehta@fredhutch.org. Hauptthemen laut MEDLINE: Donor Selection, Hematopoietic Stem Cell Transplantation, Histocompatibility Testing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The landscape of HLA matching in hematopoietic cell transplantation (HCT) is continuously advancing, introducing more nuanced criteria beyond traditional 10/10 HLA-A, -B, -C, and -DRB1 allele matching. For 10/10 matched donors, prioritizing a donor with a "core" permissive HLA-DPB1 mismatch is recommended over "noncore" permissive mismatches, with nonpermissive mismatches being the least prefered. In the one-antigen mismatched setting (7/8 HLA-matched), HLA-C matching, particularly avoiding high-expression mismatches at residues 116 or 77/80, is preferred over HLA-A or HLA-B mismatches. HLA B-leader matching is beneficial in both one-antigen mismatched and haploidentical HCT. Additionally, specific HLA mismatches in haploidentical HCT, such as DRB1 mismatches with DQB1 matches and DPB1 nonpermissive mismatches are linked to better outcomes. Among non-HLA factors, evidence consistently underscores the pivotal impact of donor age on overall survival. For HLA-mismatched transplants, including haploidentical HCT, avoidance of donors against whom the recipient has preformed donor-specific antibodies is paramount. Selecting a cytomegalovirus (CMV) seronegative donor is important particularly for CMV-negative recipients; however, more research is needed in the letermovir prophylaxis era. The impact of ABO-matching on transplant outcomes is debatable. Other unanswered questions include defining "younger" donors and establishing hierarchy in donor selection based on factors like CMV status, ABO compatibility, or sex-mismatch, to name a few. Future research addressing these issues will refine donor selection algorithms and improve transplant success. In conclusion, selecting a donor for HCT requires multifaceted considerations, integrating evolving HLA-matching criteria and non-HLA factors, to optimize HCT outcomes in this rapidly advancing field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Donor SelectionHematopoietic Stem Cell TransplantationHistocompatibility TestingHumansHLA AntigensTissue DonorsHistocompatibility

Stichwörter der Autor:innen

B-leaderHLA-matched donorHaploidenticalMismatched donorNon-HLA factors

Substanzen

HLA Antigens

Autor:innen und Institutionen

  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA. Electronic address: rmehta@fredhutch.org.

Zitieren

APA

Mehta, R. S. (2024). SOHO State of the Art Updates and Next Questions | Current Status and Future Directions of Donor Selection. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.05.011

Vancouver

Mehta RS. SOHO State of the Art Updates and Next Questions | Current Status and Future Directions of Donor Selection. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.05.011

BibTeX
@article{Mehta2024,
  author = {Mehta, Rohtesh S},
  title = {SOHO State of the Art Updates and Next Questions | Current Status and Future Directions of Donor Selection},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  doi = {10.1016/j.clml.2024.05.011}
}
Kostenlos starten →